Phase I Study of Anti-Cd3 X Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Prostate Cancer - Egypt
doi 10.1155/2015/285193
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

A Novel Asymmetrical Anti-Her2/Cd3 Bispecific Antibody Exhibits Potent Cytotoxicity for HER2-positive Tumor Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Imaging Metastatic Castration-Resistant Prostate Cancer Patients With 89Zr-Dfo-Mstp2109a Anti-Steap1 Antibody

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Urologic Clinics of North America
Urology
2012English

Heterogeneous Ensembles for Predicting Survival of Metastatic, Castrate-Resistant Prostate Cancer Patients

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2016English

Initial Experience With the Bispecific Anti-Cea Anti-Cd3 Antibody and Its Expected Impact on Future Treatment for Patients With Colorectal Cancer

ESMO Open
Cancer ResearchOncology
2018English

A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

Evidence for the Efficacy of Enzalutamide in Postchemotherapy Metastatic Castrate-Resistant Prostate Cancer

Therapeutic Advances in Urology
Urology
2013English

An Anti–glypican 3/Cd3 Bispecific T Cell–redirecting Antibody for Treatment of Solid Tumors

Science Translational Medicine
Medicine
2017English

Molecular Drivers of Metastatic Castrate-Resistant Prostate Cancer: New Roads to Resistance

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy